CN114008034A - 1-磷酸鞘氨醇受体调节剂 - Google Patents

1-磷酸鞘氨醇受体调节剂 Download PDF

Info

Publication number
CN114008034A
CN114008034A CN202080031713.8A CN202080031713A CN114008034A CN 114008034 A CN114008034 A CN 114008034A CN 202080031713 A CN202080031713 A CN 202080031713A CN 114008034 A CN114008034 A CN 114008034A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
receptor
salts
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080031713.8A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·特恩布尔
埃丝特·马丁伯勒
莫里斯·马西尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Receptos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptos LLC filed Critical Receptos LLC
Publication of CN114008034A publication Critical patent/CN114008034A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080031713.8A 2019-04-26 2020-03-27 1-磷酸鞘氨醇受体调节剂 Pending CN114008034A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839495P 2019-04-26 2019-04-26
US62/839,495 2019-04-26
PCT/US2020/025142 WO2020219207A1 (en) 2019-04-26 2020-03-27 Sphingosine 1 phosphate receptor modulator

Publications (1)

Publication Number Publication Date
CN114008034A true CN114008034A (zh) 2022-02-01

Family

ID=72941745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031713.8A Pending CN114008034A (zh) 2019-04-26 2020-03-27 1-磷酸鞘氨醇受体调节剂

Country Status (6)

Country Link
US (1) US20220227722A1 (https=)
EP (1) EP3959204A4 (https=)
JP (1) JP2022529845A (https=)
KR (1) KR20220007065A (https=)
CN (1) CN114008034A (https=)
WO (1) WO2020219207A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099469A1 (en) * 2019-11-22 2021-05-27 Basf Coatings Gmbh Electrodeposition coating material containing catechol derivatives as anticorrosion agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
MX2012005560A (es) * 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
EP3280703A1 (en) * 2015-04-06 2018-02-14 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
CA3061201A1 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection

Also Published As

Publication number Publication date
EP3959204A4 (en) 2022-12-28
EP3959204A1 (en) 2022-03-02
JP2022529845A (ja) 2022-06-24
US20220227722A1 (en) 2022-07-21
WO2020219207A1 (en) 2020-10-29
KR20220007065A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
EP4332102A1 (en) Isoquinolone compound and use thereof
AU2021389180A9 (en) Heteroaryl carboxamide compound
JP6830888B2 (ja) Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法
EP3626241B1 (en) Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
RU2704251C2 (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
RS62695B1 (sr) Novi jak1 selektivni inhibitori i njihove upotrebe
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
KR20190002468A (ko) N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태
TW201731824A (zh) α４β７整合蛋白抑制劑
UA127506C2 (uk) ПОХІДНІ ПІРОЛО[1,2-b]ПІРИДАЗИНУ
CN117460726A (zh) (3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新颖固体形式
AU2017200820A1 (en) Base addition salts of nitroxoline and uses thereof
EA036964B1 (ru) Способ получения производных диаминопиримидина и их промежуточные соединения
JP2020525475A (ja) Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形
EP2690087B1 (en) New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same
JP2017521489A (ja) ピリミジン化合物およびその使用方法
KR20200044155A (ko) 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형
CN114008034A (zh) 1-磷酸鞘氨醇受体调节剂
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
CN109553604B (zh) 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
JP7752629B2 (ja) スフィンゴシン１ホスフェート受容体モジュレーター
EP4582086A2 (en) Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220201